Search results

818 results

Sorted by Date . Sort by Relevance

  1. Few women use contraception perfectly (that is, exactly in accordance with the product instructions) and consistently. Pregnancy rates during typical use reflect effectiveness of a method among women who use the method incorrectly or inconsistently. Few data are available on typical use of any contraceptive method among women in the UK. Much of the data on contraceptive effectiveness used in the guideline come from clinical trials or surveys undertaken in other countries such as the USA. Large prospective cohort studies are needed to compare the contraceptive effectiveness of LARC methods with non‑LARC methods during typical use in the UK.

    Recommendation ID CG30/1 Question Few women use contraception perfectly (that is, exactly in accordance with the product instructions)

  2. In addition to individual circumstances and needs, a woman's choice and acceptance of LARC may be influenced by potential health disbenefits (side effects and risks) as well as non‑contraceptive benefits of LARC (such as alleviation of menorrhagia). Large population studies of appropriate design are needed to determine the effect of these factors on the uptake of LARC methods and the implications for NHS resources.

    Recommendation ID CG30/3 Question In addition to individual circumstances and needs, a woman's choice and acceptance of LARC may be influenced

  3. In patients with negative MRI (Likert score 1 or 2), what is the next best diagnostic investigation to rule out clinically significant prostate cancer? What is the diagnostic accuracy of transperineal mapping biopsy compared with transperineal non-mapping biopsy in the diagnosis of clinically significant prostate cancer?

    Recommendation ID NG131/7 Question In patients with negative MRI (Likert score 1 or 2), what is the next best diagnostic investigation

  4. What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of supported digital cognitive–behavioural therapy (CBT) compared with unsupported digital CBT in young people aged 12 to 18 years with mild depression, and what are the key components of the interventions that influence effectiveness?

    Recommendation ID NG134/2 Question What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of supported

  5. The committee recommended further research to determine if using the lead‑I electrocardiogram (ECG) devices in primary care for people with signs or symptoms of atrial fibrillation, and an irregular pulse, increases the number of people with atrial fibrillation (including paroxysmal) detected,  ompared with current practice (that is, a 12‑lead ECG done later). The committee considered the feasibility of collecting data to see if using the lead‑I ECG devices increased the detection of atrial fibrillation that would be missed if only 12‑lead ECGs done later were available. It noted that even if a lead‑I ECG is used and atrial fibrillation is detected, a subsequent 12‑lead ECG would still be done to check for structural cardiac abnormalities and inform further management decisions. The committee concluded that practices using lead‑I ECG devices could determine the number of additional cases of atrial fibrillation detected by the devices. This can be done by identifying people with a confirmed positive lead‑I ECG for atrial fibrillation who subsequently had a 12‑lead ECG that was negative because the atrial fibrillation had stopped. The committee also considered that data collected on the time between the initial lead‑I ECG and the subsequent 12‑lead ECG would be useful.

    Recommendation ID DG35/1 Question The committee recommended further research to determine if using the lead‑I electrocardiogram (ECG) devices

  6. The effect of injectable contraceptives on bone mineral density in women who have used DMPA for longer than 2 years is uncertain. Adequately powered surveys or cross‑sectional studies are needed to examine the recovery of bone mineral density after discontinuation of DMPA after long‑term and very long‑term use. Studies are also needed to examine the risk of bone fractures in older women.

    Recommendation ID CG30/4 Question The effect of injectable contraceptives on bone mineral density in women who have used DMPA for longer

  7. What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of a brief psychosocial intervention as reported by the IMPACT trial, but delivered by practitioners other than psychiatrists and in other settings, including primary care, to young people aged 12 to 18 years with mild or moderate to severe depression?

    Recommendation ID NG134/4 Question What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of a brief

  8. Lower limb peripheral arterial disease

    Everything NICE has said on diagnosing and managing lower limb peripheral arterial disease in an interactive flowchart

  9. Osteoarthritis

    Everything NICE has said on the care and management of osteoarthritis in adults in an interactive flowchart

  10. Head injury

    Everything NICE has said on triage, assessment, investigation and management of head injury in infants, children and adults in an interactive flowchart

  11. Violence and aggression

    Everything NICE has said on managing violence in mental health, health and community settings in an interactive flowchart

  12. Eye conditions

    Everything NICE has said on eye conditions in an interactive flowchart

  13. Motor neurone disease

    Everything NICE has said on assessing and managing motor neurone disease in adults in an interactive flowchart

  14. Parkinson's disease

    Everything NICE has said on diagnosing and managing Parkinson's disease in adults in primary and secondary care in an interactive flowchart

  15. Musculoskeletal conditions

    Everything NICE has said on musculoskeletal conditions in an interactive flowchart

  16. Medicines optimisation

    Everything NICE has said on shared decision-making and processes to optimise medicines and support adherence in an interactive flowchart

  17. Familial hypercholesterolaemia

    Everything NICE has said on familial hypercholesterolaemia in an interactive flowchart

  18. Ulcerative colitis

    Everything NICE has said on managing ulcerative colitis in adults, children and young people in an interactive flowchart

  19. Crohn's disease

    Everything NICE has said on managing Crohn's disease in children, young people and adults in an interactive flowchart

  20. Myeloma

    Everything NICE has said on diagnosing and managing myeloma, and preventing and managing its complications in an interactive flowchart

  21. Glaucoma

    Everything NICE has said on assessing, treating and managing glaucoma in adults in an interactive flowchart

  22. Ectopic pregnancy and miscarriage

    Everything NICE has said on diagnosing and managing tubal ectopic pregnancy and miscarriage in early pregnancy in an interactive flowchart.

  23. Local formulary development

    Everything NICE has said on systems and processes for developing and updating local formularies in an interactive flowchart